Thymic carcinoma
Conditions
Interventions
1) S-1 is orally administered twice a day at day 1-14 and day 29-
42.Dose of S-1: 80mg/m2/day, 40mg/m2/dose x 2 times
2) Cisplatin 60 mg/m2/day at day 1 and day29.
3) Daily radiation at 2.0 Gy/ti
Sponsors
Fukuda Minoru
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Patients with thymic carcinoma confirmed histologically. 2. Patients without treatment history of chemotherapy,radiation and surgical resection for thymic carcinoma. 3. Patients with unresectable locally advanced cancer and with Masaoka stage classification, stage III. Eligible for only metastasis to supraclavicular fossa or mediastinal lymph node with Masaoka stage classification, stage IVb. 4. Patients who is judged that radical irradiation is possible by a treatment plan of radiotherapist. 5. Patients without active double cancer. 6. Patient is at least 20 years of age (at enrollment date). 7. Performance status (ECOG): 0-1 8. The latest clinical laboratory test within 14 days prior to enrollment (it is eligible on the same day 2 weeks before the enrolment day) meets the following all standard. 1) WBC >= 3000/mm3 or neutrophil count >=1,500/mm3 2) Hemoglobin >= 9.0g/dL 3) Platelet count>= 100,000/mm3 4) AST, ALT = 60 mL/min (Cockcroft-Gault method, 24 hrs method) 7) PaO2 >= 60 Torr or SpO2 >= 90% 9. Patients providing the written informed consent. 10. Patients with life expectancy of at least 3 months.
Exclusion criteria
Exclusion criteria: 1. Patients who requires urgent radiation therapy with a symptom of superior vena cava syndrome 2. Patients with serious complications : such as uncontrollable angina pectoris, myocardial infarction within 3 months and heart failure, uncontrollable diabetes mellitus,hypertension and serious infection. 3. Patients with interstitial pneumonia confirmed by chest X-ray. 4. Patients having complications judged to affect the enforcement of treatment. 5. Patients with anamnesis of severe hypersensitivity. 6. Patients with pregnant or possibly pregnant. Patients with nursing. 7. Patients who are different for the participation in the study by complication of mental disease or psychiatric symptom. 8. Any other patients who are regarded as unsuitable for this study by the investigators.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| response rate | — |
Secondary
| Measure | Time frame |
|---|---|
| Overall survival (OS) Progression free survival (PFS) Adverse event (AE) | — |
Contacts
Public ContactMinoru Fukuda
Nagasaki University Hospital
Outcome results
None listed